摘要
目的分析赫赛汀联合芙瑞治疗方案对乳腺癌患者血清糖链抗原-153(CA-153)、前列腺特异性抗原(PSA)、C角蛋白19片段抗原21-1(CYFRA21-1)水平及血常规的影响。方法选择2014年6月至2016年6月期间我院收治的96例乳腺癌患者,随机均分为对照组和观察组。对照组在化疗的基础上联用芙瑞,观察组在化疗的基础上联用赫赛汀和芙瑞。2组患者治疗前、后分别采集空腹静脉血用于检测血清因子水平及外周血中血红蛋白、白细胞数及血小板指标,统计患者治疗疗效及不良反应。结果治疗前,两组患者血清中CA-153、PSA及CYFRA21-1水平差别无统计学意义(P>0.05);治疗7d后,两组患者血清中CA-153、PSA及CYFRA21-1水平明显降低,但观察组CA-153(1.45±0.16U/m L)、TPSA(0.12±0.05ng/m L)、FPSA(12.82±2.41pg/m L)及CYFRA21-1(1.74±0.48ng/m L)明显低于对照组CA-153(3.23±0.28U/m L)、TPSA(0.23±0.07ng/m L)、FPSA(20.56±2.79pg/m L)及CYFRA21-1(3.18±0.53 ng/m L),差异有统计学意义(P<0.05)。治疗前,两组患者的血红蛋白、白细胞数及血小板指标差别无统计学意义(P>0.05);治疗7d后,观察组血红蛋白、白细胞数及血小板指标无显著性变化(P>0.05);对照组血红蛋白、白细胞数及血小板指标明显下降,且与治疗7d后的观察组血红蛋白、白细胞数及血小板指标对比,差异有统计学意义(P<0.05)。观察组的缓解率85.42%(41/48)明显高于对照组缓解率66.67%(32/48),差异有统计学意义(P<0.05)。结论采用赫赛汀联合芙瑞治疗乳腺癌患者,可减少患者血清中CA-153,PSA,CYFRA21-1的分泌,减少化疗对患者造血功能的损伤,提高患者的临床疗效。
Objective To analyze the Herceptin combined with Winfrey therapy on breast cancer patients＇ CA- 153 ,PSA, CYFRA21-1 levels and blood routine result. Methods 96 cases of breast cancer patients from June 2014 to June 2016 in our hospital were randomly divided into the control group and the observation group. The control group was treated with chemotherapy by Winfrey, while the observation group was treated with chemotherapy with Herceptin and winfrey. Fasting blood was collected before and after treatment in both 2 groups for the detection of serum factors, hemoglobin level, WBC count and platelet count in peripheral blood, also the curative effect and adverse reactions of the patients were recorded. Results Before treatment, two groups＇ serum CA- 153, PSA and CYFRA21-1 content had no significant difference （ P 〉 0.05 ） ; after treatment, two groups＇ serum CA- 153, PSA and CYFRA21 - 1 were significantly decreased, but the observation group had CA- 153 （ 1.45± 0. 16U/mL）, TPSA （0. 12 ±0.05ng/mL）, FPSA （ 12.82 ± 2.41pg/mL） and CYFRA21-1 （1. 74 ± 0.48ng/mL）, which was significantly lower than the control group with CA-153 （3.23 ±0.28U/mL） ,TPSA（0.23 ±0.07ng/mL） ,FPSA（20.56± 8.79pg/mL） and CYFRA21-1 （3.18 ± 0.53ng/mL） （P 〈 0.05）. Before treatment, there was no significant difference between the two groups＇ hemoglobin, blood ceils and platelet index （ P 〉 0. 05 ） ; after 7 days of treatment, the observation group＇ s hemoglobin, blood cells and platelet index had no significant difference （P 〉 0. 05 ） ; while the control group＇s hemoglobin, blood cells and platelets significantly decreased. Compared with the observation group＇s hemoglobin after 7 days＇ treatment,the control group＇s blood cell and platelet index was significant different （P 〈 0.05 ）. The remission rate of the observation group was 85.42% （41/48）, which was significantly higher than that of the control group which was 66.67% （ 32/48 ） （ P 〈 0.05 ）. Conclus
出处
《标记免疫分析与临床》
CAS
2018年第2期211-214,共4页
Labeled Immunoassays and Clinical Medicine
